Parexel

Parexel is a leading global contract research organization (CRO) that conducts clinical trials and provides comprehensive biopharmaceutical development services on behalf of pharmaceutical and biotechnology clients. Founded in 1982 and headquartered in Raleigh, North Carolina, Parexel operates across 100+ countries with approximately 21,000 employees worldwide. The company offers end-to-end solutions throughout drug development, from portfolio optimization and regulatory strategy to Phase I-IV clinical trials, market access planning, and real-world evidence services. Parexel specializes in complex therapeutic areas including oncology, neuroscience, immunology, rare diseases, infectious diseases, vaccines, and cell and gene therapies. As one of the world's largest CROs, Parexel combines clinical expertise with advanced technology and AI capabilities to accelerate drug development timelines. The company is distinguished by its team of over 80 ex-regulatory agency professionals (FDA, EMA, NMPA, MHRA, and others) and maintains a global network of nearly 2,500 clinical sites. Currently owned by EQT Private Equity and Goldman Sachs Asset Management since November 2021, Parexel continues to drive innovation in clinical research through strategic partnerships with technology companies and healthcare providers.